As mentioned above, the notions that NF-κB activation is an event that promotes melanoma progression and that ROS-mediated increases in NF-κB sequentially drive the antiapoptotic process have long been known; NF-κB promotes the upregulation of antiapoptotic proteins just detectable in melanocytic nevi, and that increases during melanoma progression and metastasis; between them, there is the tumor necrosis factor receptor-associated factor 1 and 2 (TRAF1, TRAF2), c-IAP1, c-IAP2 proteins, the melanoma inhibitor of apoptosis (ML-IAP), and Bcl-2 proteins, as mentioned above [172,173]. Here, BCL2 is linked to melanoma.